Diabetes Therapy: DPP-4 Inhibitor and Long-Acting Insulin Combination
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus often fail to maintain long-term glycemic control, are associated with side effects, and do not adequately prevent or delay the progression of complications, leading to high rates of hyperglycemia-associated complications.
Innovation Solution
The combination of a long-acting insulin, such as insulin glargine or insulin detemir, with a DPP-4 inhibitor like linagliptin for simultaneous, separate, or sequential administration, providing improved glycemic control and reducing the risk of complications through complementary mechanisms of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for type 2 diabetes mellitus are used, then glycemic control is achieved initially, but long-term glycemic control deteriorates and complications progress
Solution Approach 1:
The patent combines linagliptin (a DPP-4 inhibitor) with long-acting insulin to create a fixed-ratio combination product. This merging of two mechanisms of action (DPP-4 inhibition enhancing incretin effect and insulin providing basal insulin coverage) addresses the limitation of monotherapy by providing complementary glucose-lowering effects that maintain efficacy over the long term, preventing the deterioration of glycemic control that occurs with single-agent therapy.
2Quantity of substance
If conventional diabetes treatments are administered, then blood glucose levels are reduced, but side effects and adverse reactions increase
Solution Approach 1:
The patent utilizes the parameter change of combining two drugs with different mechanisms of action in fixed ratios (1:1 or 2:1 linagliptin to insulin). This parameter change allows for synergistic glucose-lowering effects at lower individual doses of each component, thereby reducing the side effects associated with higher doses of single agents while maintaining effective blood glucose control.
3Ease of operation
If monotherapy is used for diabetes treatment, then treatment simplicity is maintained, but therapeutic efficacy deteriorates over time
Solution Approach 1:
The fixed-ratio combination product merges linagliptin and long-acting insulin into a single administered unit, maintaining ease of operation (once-daily injection) while delivering the synergistic therapeutic effects of both agents. This eliminates the need for patients to manage multiple separate medications, preserving simplicity while significantly improving and sustaining therapeutic efficacy compared to monotherapy.
4Reliability
If diabetes complications are allowed to progress, then disease natural history is followed, but quality of life and life expectancy are reduced
Solution Approach 1:
The combination therapy takes preliminary action by providing sustained, stable glycemic control from the outset of treatment through the synergistic effects of linagliptin and insulin. By maintaining consistent glucose levels and preventing glycemic variability, the treatment proactively prevents the development and progression of hyperglycemia-associated complications before they can occur, rather than merely responding to established disease progression.
Data Source
AI summary
The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.



